A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)

被引：0

作者：

Meric-Bernstam, Funda ^{[1
]}

Anoka, Chiedozie ^{[2
]}

Dobrowolska, Anna ^{[3
]}

Chaudhry, Anubhavini ^{[2
]}

Rowbottom, Jacqui ^{[2
]}

Gustavson, Mark ^{[2
]}

Puvvada, Soham ^{[2
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] AstraZeneca, Cambridge, England

[3] AstraZeneca Pharma Poland, Warsaw, Poland

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

296

引用

页码：S156 / S156

页数：1